ATOSSA THERAPEUTICS, INC. Cash and Cash Equivalents, Period Increase (Decrease)
ATOSSA THERAPEUTICS, INC. (ATOS) reported Cash and Cash Equivalents, Period Increase (Decrease) of $4.19 million for the 12-month period ending 2017-12-31, per its 10-K filed 2018-03-08.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2018-03-08
- ATOSSA THERAPEUTICS, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-12-31 was $4.48M.
- ATOSSA THERAPEUTICS, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-09-30 was -$956.36K, a 129.91% decline year-over-year.
- ATOSSA THERAPEUTICS, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-06-30 was $2.52M.
- ATOSSA THERAPEUTICS, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-03-31 was -$1.86M.
- ATOSSA THERAPEUTICS, INC. cash and cash equivalents, period increase (decrease) for fiscal 2017 was $4.19M.
- ATOSSA THERAPEUTICS, INC. cash and cash equivalents, period increase (decrease) for fiscal 2016 was -$687.93K.
- ATOSSA THERAPEUTICS, INC. cash and cash equivalents, period increase (decrease) for fiscal 2015 was -$4.78M, a 321.67% decline from fiscal 2014.
- ATOSSA THERAPEUTICS, INC. cash and cash equivalents, period increase (decrease) for fiscal 2014 was $2.16M, a 53.25% decline from fiscal 2013.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month | Cash and Cash Equivalents, Period Increase (Decrease) 41 month | Cash and Cash Equivalents, Period Increase (Decrease) 44 month | Cash and Cash Equivalents, Period Increase (Decrease) 47 month | Cash and Cash Equivalents, Period Increase (Decrease) 50 month | Cash and Cash Equivalents, Period Increase (Decrease) 53 month | Cash and Cash Equivalents, Period Increase (Decrease) 56 month | Cash and Cash Equivalents, Period Increase (Decrease) 59 month |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2017-12-31 | $4.48M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-08 | $3.53M derived: sum of 2 quarters · filed 2018-03-08 | $6.05M derived: sum of 3 quarters · filed 2018-03-08 | $4.19M 10-K · filed 2018-03-08 | |||||||
| 2017-09-30 | -$956.36K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-13 | $1.57M derived: sum of 2 quarters · filed 2017-11-13 | -$294.30K 10-Q · filed 2017-11-13 | -$1.65M derived: sum of 4 quarters · filed 2018-03-08 | |||||||
| 2017-06-30 | $2.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-14 | $662.06K 10-Q · filed 2017-08-14 | -$698.15K derived: sum of 3 quarters · filed 2018-03-08 | $2.50M derived: sum of 4 quarters · filed 2018-03-08 | |||||||
| 2017-03-31 | -$1.86M 10-Q · filed 2017-05-11 | -$3.22M derived: sum of 2 quarters · filed 2018-03-08 | -$23.86K derived: sum of 3 quarters · filed 2018-03-08 | -$1.72M derived: sum of 4 quarters · filed 2018-03-08 | |||||||
| 2016-12-31 | -$1.36M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-08 | $1.84M derived: sum of 2 quarters · filed 2018-03-08 | $145.31K derived: sum of 3 quarters · filed 2018-03-08 | -$687.93K 10-K · filed 2018-03-08 | |||||||
| 2016-09-30 | $3.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-13 | $1.51M derived: sum of 2 quarters · filed 2017-11-13 | $672.28K 10-Q · filed 2017-11-13 | -$3.45M derived: sum of 4 quarters · filed 2017-11-13 | |||||||
| 2016-06-30 | -$1.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-14 | -$2.53M 10-Q · filed 2017-08-14 | -$6.65M derived: sum of 3 quarters · filed 2017-08-14 | -$10.21M derived: sum of 4 quarters · filed 2017-08-14 | |||||||
| 2016-03-31 | -$833.24K 10-Q · filed 2017-05-11 | -$4.96M derived: sum of 2 quarters · filed 2017-05-11 | -$8.52M derived: sum of 3 quarters · filed 2017-05-11 | -$6.85M derived: sum of 4 quarters · filed 2017-05-11 | |||||||
| 2015-12-31 | -$4.12M derived: 10-K/A 12 month − 10-Q/A 9 month · filed 2017-03-21 | -$7.69M derived: sum of 2 quarters · filed 2017-03-21 | -$6.01M derived: sum of 3 quarters · filed 2017-03-21 | -$4.78M 10-K/A · filed 2017-03-21 | |||||||
| 2015-09-30 | -$3.56M derived: 10-Q/A 9 month − 10-Q/A 6 month · filed 2017-03-21 | -$1.89M derived: sum of 2 quarters · filed 2017-03-21 | -$661.28K 10-Q/A · filed 2017-03-21 | -$3.53M derived: sum of 4 quarters · filed 2017-03-21 | |||||||
| 2015-06-30 | $1.67M derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2017-03-21 | $2.90M 10-Q/A · filed 2017-03-21 | $28.68K derived: sum of 3 quarters · filed 2017-03-21 | -$2.90M derived: sum of 4 quarters · filed 2017-03-21 | |||||||
| 2015-03-31 | $1.23M 10-Q/A · filed 2017-03-21 | -$1.65M derived: sum of 2 quarters · filed 2017-03-21 | -$4.57M derived: sum of 3 quarters · filed 2017-03-21 | -$6.86M derived: sum of 4 quarters · filed 2017-03-21 | |||||||
| 2014-12-31 | -$2.87M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-30 | -$5.80M derived: sum of 2 quarters · filed 2016-03-30 | -$8.09M derived: sum of 3 quarters · filed 2016-03-30 | $2.16M 10-K · filed 2016-03-30 | |||||||
| 2014-09-30 | -$2.92M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-12 | -$5.22M derived: sum of 2 quarters · filed 2015-11-12 | $5.03M 10-Q · filed 2015-11-12 | $3.68M derived: sum of 4 quarters · filed 2015-11-12 | |||||||
| 2014-06-30 | -$2.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-06 | $7.96M 10-Q · filed 2015-08-06 | $6.60M derived: sum of 3 quarters · filed 2015-08-06 | $11.86M derived: sum of 4 quarters · filed 2015-08-06 | |||||||
| 2014-03-31 | $10.25M 10-Q · filed 2015-05-13 | $8.90M derived: sum of 2 quarters · filed 2015-05-13 | $14.15M derived: sum of 3 quarters · filed 2015-05-13 | $15.21M derived: sum of 4 quarters · filed 2015-05-13 | $16.59M 10-Q · filed 2014-05-14 | ||||||
| 2013-12-31 | -$1.35M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-30 | $3.90M derived: sum of 2 quarters · filed 2015-03-30 | $4.96M derived: sum of 3 quarters · filed 2015-03-30 | $4.62M 10-K · filed 2015-03-30 | $6.34M 10-K · filed 2014-03-27 | ||||||
| 2013-09-30 | $5.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-12 | $6.31M derived: sum of 2 quarters · filed 2014-11-12 | $5.97M 10-Q · filed 2014-11-12 | $7.27M derived: sum of 4 quarters · filed 2014-11-12 | $7.69M 10-Q · filed 2013-11-12 | ||||||
| 2013-06-30 | $1.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-12 | $714.32K 10-Q · filed 2014-08-12 | $2.02M derived: sum of 3 quarters · filed 2014-08-12 | $2.35M derived: sum of 4 quarters · filed 2014-08-12 | $2.44M 10-Q · filed 2013-08-14 | ||||||
| 2013-03-31 | -$340.00K 10-Q · filed 2014-05-14 | $966.63K derived: sum of 2 quarters · filed 2014-05-14 | $1.30M derived: sum of 3 quarters · filed 2014-05-14 | $485.70K derived: sum of 4 quarters · filed 2014-05-14 | $1.39M 10-Q · filed 2013-05-15 | ||||||
| 2012-12-31 | $1.31M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-27 | $1.64M derived: sum of 2 quarters · filed 2014-03-27 | $825.70K derived: sum of 3 quarters · filed 2014-03-27 | -$185.62K 10-K · filed 2014-03-27 | $1.73M 10-K · filed 2013-03-28 | ||||||
| 2012-09-30 | $330.57K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-12 | -$480.92K derived: sum of 2 quarters · filed 2013-11-12 | -$1.49M 10-Q · filed 2013-11-12 | -$2.59M derived: sum of 4 quarters · filed 2013-11-12 | $418.57K 10-Q/A · filed 2013-01-22 | ||||||
| 2012-06-30 | -$811.50K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-14 | -$1.82M 10-Q · filed 2013-08-14 | -$2.92M derived: sum of 3 quarters · filed 2013-08-14 | ||||||||
| 2012-03-31 | -$1.01M 10-Q · filed 2013-05-15 | -$2.11M derived: sum of 2 quarters · filed 2013-05-15 | |||||||||
| 2011-12-31 | -$1.10M derived: 10-K 12 month − 10-Q/A 9 month · filed 2013-03-28 | $1.90M 10-K · filed 2013-03-28 | |||||||||
| 2011-09-30 | $3.00M 10-Q/A · filed 2013-01-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |